[Research Progress of New Generation EGFR-TKIs after Third-generation]

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Non-small cell lung cancer (NSCLC) has a high mortality rate globally.
• Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have improved outcomes for NSCLC patients, but acquired resistance, often via T790M mutations, limits long-term efficacy.
• Third-generation EGFR-TKIs, like osimertinib, are effective against T790M resistance but are eventually overcome by new resistance mechanisms.

Purpose of the Study:

• To review the research progress on next-generation EGFR-TKIs designed to overcome resistance after third-generation treatments.
• To provide insights for future research and clinical strategies in managing advanced NSCLC.

Main Methods:

• Literature review of preclinical and clinical studies on novel EGFR-TKIs.
• Analysis of emerging resistance mechanisms to third-generation EGFR-TKIs.
• Summary of therapeutic strategies targeting post-third-generation resistance.

Main Results:

• Resistance to third-generation EGFR-TKIs can arise from various mechanisms including C797S mutations, MET amplification, RAS/BRAF mutations, and histological transformation (SCLC, EMT).
• Several novel EGFR-TKIs are under investigation, showing promise in preclinical models and early clinical trials against these resistance mechanisms.
• No standard treatment currently exists for patients resistant to third-generation EGFR-TKIs.

Conclusions:

• Acquired resistance to EGFR-TKIs remains a significant challenge in NSCLC treatment.
• Next-generation EGFR-TKIs represent a promising therapeutic avenue for overcoming resistance to current treatments.
• Further research and clinical development are crucial to establish effective treatment paradigms for patients with advanced, resistant NSCLC.